View in EDS HTML Full Text PDF Full Text

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.

Saved in:
Bibliographic Details
Title: Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
Authors: Bahlis NJ; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada., Zonder J; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA., Karlin L; Department of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France., Plesner T; Vejle Hospital, University of Southern Denmark, Vejle, Denmark., Paris L; Division of Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Wrobel T; Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland., Hungria V; Clínica Medica São Germano, São Paulo, Brazil., Besemer B; Abteilung für Innere Medizin II, Universitätsklinikum Tübingen der Eberhard-Karls-Universität, Tübingen, Germany., Crusoe E; Hospital São Rafael, Instituto D'Or de Pesquisa e Ensino and Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia-HUPES-UFBA, Salvador, Brazil., Silkjaer T; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Perrot A; Université de Toulouse, CHU de Toulouse, Service d'Hématologie, Toulouse, France., Moreau P; Hematology Department, University Hospital Hôtel-Dieu, Nantes, France., Wu KL; ZNA Stuivenberg, Antwerp, Belgium., Delimpasi S; Evangelismos Hospital, Athens, Greece., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.; Department of Medicine, Korea University, Seoul, South Korea., Levin MD; Albert Schweitzer Hospital, Dordrecht, The Netherlands., Mangiacavalli S; Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy., Nnane I; Johnson & Johnson, Washington, PA, USA., Kim YJ; Johnson & Johnson, Raritan, NJ, USA., Krevvata M; Johnson & Johnson, Washington, PA, USA., Sha L; Johnson & Johnson, Shanghai, China., Wroblewski S; Johnson & Johnson, Washington, PA, USA., Tuozzo A; Johnson & Johnson, Washington, PA, USA., Carson R; Johnson & Johnson, Washington, PA, USA., Facon T; University of Lille, CHU Lille, Lille, France.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2025 Dec; Vol. 66 (14), pp. 2685-2696. Date of Electronic Publication: 2025 Oct 03.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41041907
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Bahlis+NJ%22">Bahlis NJ</searchLink>; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada.<br /><searchLink fieldCode="AU" term="%22Zonder+J%22">Zonder J</searchLink>; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.<br /><searchLink fieldCode="AU" term="%22Karlin+L%22">Karlin L</searchLink>; Department of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.<br /><searchLink fieldCode="AU" term="%22Plesner+T%22">Plesner T</searchLink>; Vejle Hospital, University of Southern Denmark, Vejle, Denmark.<br /><searchLink fieldCode="AU" term="%22Paris+L%22">Paris L</searchLink>; Division of Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.<br /><searchLink fieldCode="AU" term="%22Wrobel+T%22">Wrobel T</searchLink>; Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland.<br /><searchLink fieldCode="AU" term="%22Hungria+V%22">Hungria V</searchLink>; Clínica Medica São Germano, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Besemer+B%22">Besemer B</searchLink>; Abteilung für Innere Medizin II, Universitätsklinikum Tübingen der Eberhard-Karls-Universität, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Crusoe+E%22">Crusoe E</searchLink>; Hospital São Rafael, Instituto D'Or de Pesquisa e Ensino and Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia-HUPES-UFBA, Salvador, Brazil.<br /><searchLink fieldCode="AU" term="%22Silkjaer+T%22">Silkjaer T</searchLink>; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.<br /><searchLink fieldCode="AU" term="%22Perrot+A%22">Perrot A</searchLink>; Université de Toulouse, CHU de Toulouse, Service d'Hématologie, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22Moreau+P%22">Moreau P</searchLink>; Hematology Department, University Hospital Hôtel-Dieu, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Wu+KL%22">Wu KL</searchLink>; ZNA Stuivenberg, Antwerp, Belgium.<br /><searchLink fieldCode="AU" term="%22Delimpasi+S%22">Delimpasi S</searchLink>; Evangelismos Hospital, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.; Department of Medicine, Korea University, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Levin+MD%22">Levin MD</searchLink>; Albert Schweitzer Hospital, Dordrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mangiacavalli+S%22">Mangiacavalli S</searchLink>; Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.<br /><searchLink fieldCode="AU" term="%22Nnane+I%22">Nnane I</searchLink>; Johnson & Johnson, Washington, PA, USA.<br /><searchLink fieldCode="AU" term="%22Kim+YJ%22">Kim YJ</searchLink>; Johnson & Johnson, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Krevvata+M%22">Krevvata M</searchLink>; Johnson & Johnson, Washington, PA, USA.<br /><searchLink fieldCode="AU" term="%22Sha+L%22">Sha L</searchLink>; Johnson & Johnson, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wroblewski+S%22">Wroblewski S</searchLink>; Johnson & Johnson, Washington, PA, USA.<br /><searchLink fieldCode="AU" term="%22Tuozzo+A%22">Tuozzo A</searchLink>; Johnson & Johnson, Washington, PA, USA.<br /><searchLink fieldCode="AU" term="%22Carson+R%22">Carson R</searchLink>; Johnson & Johnson, Washington, PA, USA.<br /><searchLink fieldCode="AU" term="%22Facon+T%22">Facon T</searchLink>; University of Lille, CHU Lille, Lille, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007422%22">Leukemia & lymphoma</searchLink> [Leuk Lymphoma] 2025 Dec; Vol. 66 (14), pp. 2685-2696. <i>Date of Electronic Publication: </i>2025 Oct 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9007422 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1029-2403 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210268022%22">10268022 </searchLink><i>NLM ISO Abbreviation: </i>Leuk Lymphoma <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41041907
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/10428194.2025.2561117
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2685
    Titles:
      – TitleFull: Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bahlis NJ
      – PersonEntity:
          Name:
            NameFull: Zonder J
      – PersonEntity:
          Name:
            NameFull: Karlin L
      – PersonEntity:
          Name:
            NameFull: Plesner T
      – PersonEntity:
          Name:
            NameFull: Paris L
      – PersonEntity:
          Name:
            NameFull: Wrobel T
      – PersonEntity:
          Name:
            NameFull: Hungria V
      – PersonEntity:
          Name:
            NameFull: Besemer B
      – PersonEntity:
          Name:
            NameFull: Crusoe E
      – PersonEntity:
          Name:
            NameFull: Silkjaer T
      – PersonEntity:
          Name:
            NameFull: Perrot A
      – PersonEntity:
          Name:
            NameFull: Moreau P
      – PersonEntity:
          Name:
            NameFull: Wu KL
      – PersonEntity:
          Name:
            NameFull: Delimpasi S
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
      – PersonEntity:
          Name:
            NameFull: Levin MD
      – PersonEntity:
          Name:
            NameFull: Mangiacavalli S
      – PersonEntity:
          Name:
            NameFull: Nnane I
      – PersonEntity:
          Name:
            NameFull: Kim YJ
      – PersonEntity:
          Name:
            NameFull: Krevvata M
      – PersonEntity:
          Name:
            NameFull: Sha L
      – PersonEntity:
          Name:
            NameFull: Wroblewski S
      – PersonEntity:
          Name:
            NameFull: Tuozzo A
      – PersonEntity:
          Name:
            NameFull: Carson R
      – PersonEntity:
          Name:
            NameFull: Facon T
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1029-2403
          Numbering:
            – Type: volume
              Value: 66
            – Type: issue
              Value: 14
          Titles:
            – TitleFull: Leukemia & lymphoma
              Type: main
ResultId 1